Searched for
VOLUME PARENTERALS
Sai Parenteral’s IPO allotment likely today: Check status, GMP, other detailsSai Parenteral's IPO share allotment is expected today, with investors able to check their status on BSE or the registrar's website. The is...- Sai Parenteral IPO Day 3: 43% subscribed; here’s a look at GMP and key details; Should you invest?Sai Parenteral IPO saw 43% subscription on Day 3, with strong NII interest but weak retail participation. Despite no GMP indicating a flat ...
- Sai Parenteral IPO Day 2: Issue booked 41%; check GMP and other details. Should you apply?Sai Parenteral Limited's initial public offering is underway. The IPO ended Day 2 with over 41% subscription. The company aims to raise Rs ...
- Sai Parenteral’s IPO: Issue subscribed just 4% on day 1. Check price band, GMPSai Parenteral’s IPO opened with weak demand, subscribing just 4% on day one amid no grey market premium. While retail and NII interest rem...
- Rs 409 crore Sai Parenteral’s IPO issue opens for subscription. Check price band, GMP and to subscribe or notSai Parenteral's IPO opens for subscription, aiming to raise Rs 409 crore through a mix of fresh equity and an offer for sale. The company ...
- Amanta Healthcare shares jump another 5% after a decent debut. Should you book profits or hold?Amanta Healthcare shares extended gains after debuting at a 7% premium, reflecting moderate investor optimism despite steep valuations at 4...
- Amanta Healthcare shares to list tomorrow. Here's what GMP indicates ahead of debutAmanta Healthcare, an Ahmedabad-based pharmaceutical company, is set to debut on the market with modest expectations, indicated by a GMP of...
- Amanta Healthcare IPO subscribed nearly 83 times at close; GMP at 8%. Should you bid?Amanta Healthcare’s Rs 126 crore IPO was subscribed nearly 83 times at close, driven by NIIs and RIIs. Trading at an 8% GMP, the stock may ...
- Amanta Healthcare IPO subscribed 12.40 times on Day 2; GMP at 12% — Should you bid? Check key detailsAmanta Healthcare's Rs 126 crore IPO witnessed strong investor demand, subscribing 12.40 times on its second day, driven by retail investor...
- Amanta Healthcare IPO subscribed 3.2 times so far on Day 1; GMP at 15%. Should you bid?Amanta Healthcare's IPO witnessed strong investor demand, being oversubscribed 3.2 times on its opening day, driven by retail and non-insti...
- US-based Amneal Pharmaceuticals buys India's injectable maker Punishka Healthcare for Rs 700 croresAmneal Pharmaceuticals on Tuesday said it has acquired Ahmedabad-based injectable drug maker Puniska Healthcare Pvt. Ltd for a total value ...
- Hyderabad-based drugmaker Gland Pharma attracts bids from Torrent Pharma and BaxterIf the deal materialises, the promoter family of Ravi Penmetsa may sell its entire equity stake of nearly 60% for a valuation of over $1.2 ...
- Claris surges 18% as pharma cos in race to buy injectible bizLupin, Cipla Zydus Cadilla and US-based Amneal are competing with other global peers signaling the continuing appeal of quality Indian phar...
- Claris transfers two businesses to Japan JV for Rs 1,050 crClaris will continue to hold a 20 per cent stake in the JV, while Otsuka and Mitsui will hold 60 and 20 per cent in it, respectively, a com...
- South Africa approves six Marck Biosciences pharma productsThe South African market worth around $ 3.8 billion (2011), is growing at the rate of six per cent and is expected to reach $ 7 billion by ...
- South Africa drug authority approves Marck's 6 productsSix products have obtained approvals from MCC-South Africa, including Sterile Water for injections and Ciprofloxacin Eye Drops among others.
- Subscribe to Claris Lifesciences IPO: Angel BrokingClaris has grown at strong pace with net sales increasing at CAGR of 26.9% & net profit of 65.6%.
- Stocks to watch: Reliance MediaWorks, Dr Reddy’s Labs, Spicejet, Radico Khaitan, Shree Cement, Parenteral Drugs, Satyam Computers: Reliance MediaWorks (RMW), which is locked in a takeover battle for multiplex operator Fame with rival Inox, has challenged the sale of m...
- Abl Biotech inks MoU with CMC for researchAbl Biotechnologies Ltd said it has signed an MoU with Christian Medical College, Vellore, for joint research in several areas in managemen...
- Nirma plans pharma foray, to float armNirma, the Rs 2,243 crore detergent-maker and owner of the Nirma brand, is betting big on the pharmaceutical sector.
Load More
